婴幼儿哮喘的危险因素

目的寻找婴幼儿喘息、儿童哮喘的危险及保护因素。方法1个月~3岁肺炎患儿82例、毛细支气管炎65例、婴幼儿哮喘76例,107例正常儿童作为对照。采用向家长书面问卷调查方法询问各组婴儿既往病史、家族及个人过敏史、怀孕出生及婴幼儿喂养情况、生活条件等。结果父母任何一方有喘息史、父母任何一方有其他过敏史、父母任何一方吸烟、湿疹等个人过敏史任何一种、父(母)亲有哮喘史及过敏史、兄弟姐妹有哮喘史及过敏史、个人有过敏性鼻炎、个人有药物过敏、母妊娠期间早孕反应重、母亲是素食者、母亲文化程度低是婴幼儿哮喘的危险因素;而自然分娩、婴幼儿期补充VitD和钙剂、生后冬季户外活动时间长、每天平均睡眠时间长、住所有上下水设备是婴幼儿哮喘的保护因素。结论个人过敏史和家族过敏史为婴幼儿哮喘的主要危险因素。     

Abmessung und Analyse der Bezugsfl(a)che von Acetabulum-Prothese-Transplantation in unterschiedlichen K(o)rperlagen

Ziel ist die Analyse der Neigungslage des Beckens im Liegen und im Stehen bzw.die Beobachtung der Stabilit(a)t der Beckenfl(a)che als Beckenfl(a)che für die Acetabulum-Prothese Transplantation. 72 Testpersonen wurden je nach Status ihres Pfannengelenks in 3 Gruppen eingeteilt:Gruppe 1 "mit gesundem Pfannengelenk", Gruppe 2 "mit Arthritis" und Gruppe 3 "nach Implantation der Hüftendoprothese". Unter dem Einsatz von 3D- Digital-Instrument wurde die Fl(a)chen-Neigung vor dem Becken jeweils im Liegen und im Stehen gemessen und die Messwerte wurden verglichen. Die Fl(a)chen-Neigungen vor dem Becken bei allen 3 Gruppen (mit gesundem Pfannengelenk/mit Arthritis/nach Operation) im Liegen sind: 6.37°± 3.70°, 6. 47°± 3.52° und 4.56°±2.39°. Im Stehen sind es 7.33°±3.08°, 6.60°±3.45° und 6.74°±3.43°. Der Fl(a)chen-Neigungsunterschied vor dem Becken im Liegen und im Stehen hat keine grosse Bedeutung (P＞0.05).Die (A)nderung der Fl(a)chen-Neigung vor dem Becken vom Liegen bis zum Stehen ist kleiner als 2.5°.Die Fl(a)che vor dem Becken (pelvic anterior plane, PAP) als Bezugsfl(a)che für Hüftpfanne-Prothese Transplantation bei klinischer Operation ist stabil und verlaβlich.     

Frank压迫法阴道成形术治疗先天性无阴道

目的 探讨Frank压迫法阴道成形术治疗先天性无阴道的临床效果.方法 观察Frank法治疗159例先天性无阴道患者的治疗时间和随访治疗效果.结果 159例患者全部治疗成功,所需时间最长7个月,最短 10 d,62例已结婚,随访性生活满意.结论 对于阴道前庭部弹性好,阴道外口处有0.5cm以上陷凹的先天性无阴道患者,用Frank压迫法阴道成形术简便、安全、有效,有2cm以上阴道者,疗效更佳.     

归因方式问卷的初步修订

目的修订归因方式问卷(ASQ).方法对467名大学生进行归因方式问卷(ASQ)和Beck抑郁量表(BDI)的测定.结果①修订的归因方式问卷总体信度达到0.8429,各个分量表的信度在0.4～0.9之间.②不同抑郁水平大学生之间归因方式有显著差异,但在正性事件和内外维度上关系不稳定.结论修订的归因方式问卷的信度和效度指标符合心理测量学的要求,可作为大学生的归因方式测量工具.     

牛乳铁蛋白质量标准的研究

目的研究牛乳铁蛋白的质量标准。方法采用化学及高效液相色谱法(HPLC)进行定性鉴别； 采用HPLC法对牛乳铁蛋白的含量进行测定。结果牛乳铁蛋白的浓度在25 ～ 1 000 μg·mL^-1与其峰面积成良好的线性关系 ，r＝0.999 9。结论该法操作简便，精密度好，结果准确可靠，可作为牛乳铁蛋白质量标准的重要指标。     

尖吻蝮蛇毒中一种新类凝血酶的分离纯化

用阴离子交换色谱和凝胶过滤色谱技术,从尖吻蝮蛇毒中纯化得到一个具有凝血活性的组分.经Superdex 75 HR10/30预装柱检测,纯度达99.91%.SDS-PAGE显示为单一条带,还原、非还原条件下分子量分别为59.25k、52.58k.该组分的凝血酶比活为41.5u/mg,精氨酸酯酶比活为14.29u/mg,但不激活血浆凝血因子ⅩⅢ.EDTA不能抑制其凝血活性,而苯甲磺酰氟则产生不可逆抑制作用.结果表明该酶是一种新尖吻蝮蛇毒类凝血酶.     

通过改造工程细胞提高重组蛋白类药物产量的研究进展

哺乳动物细胞是表达蛋白类生物产品的理想宿主细胞。但是,表达水平常较低。通过对工程细胞进行改造,如抑制细胞凋亡、对细胞周期进行调控、提高翻译后加工能力、改变细胞新陈代谢的特性、实现基因组热点整合等,可有效地提高重组蛋白类药物的产量,为生物药品的规模化生产奠定基础     

乳铁蛋白对大鼠成骨细胞增殖与分化的影响

目的观察乳铁蛋白(Lf)对大鼠成骨细胞增殖分化的影响,初步探讨Lf对成骨细胞的作用机制。方法用不同浓度的Lf干预成骨细胞,在不同时间分别测定细胞数目的增殖、细胞内碱性磷酸酶活性,并用半定量RT-PCR法检测成骨细胞内RANKL/OPG mRNA基因的表达。结果Lf呈时间和浓度依赖性地促进大鼠成骨细胞增殖及碱性磷酸酶活性,每组实验在不同时间的差异均有显著的统计学意义(P<0.05),其中400μg/ml组在72h时细胞增殖数目达到最大。在碱性磷酸酶活性方面,400μg/ml组在72h时则有所下降。不同浓度Lf、不同作用时间均能促使成骨细胞中OPG mRNA表达增加,同时抑制RANKL mRNA表达。结论Lf能促进成骨细胞的增殖分化,并且能够调节成骨细胞RANKL/ OPG mRNA表达,从而抑制破骨细胞介导的骨吸收。     

At the heart of the problem: congestive cardiac failure as a cause of ascites: A narrative review

Heart failure leading to cardiac ascites is an extremely rare and underrecognized entity in clinical practice. Recognizing cardiac ascites can be difficult, especially since patients presenting with ascites may have more than 1 etiology. Various biomarkers are available to aid in the diagnosis of cardiac ascites, though with differing sensitivities and specificities. Such biomarkers include serum albumin, ascitic albumin and protein, as well as serum N-terminal pro-brain natriuretic peptide (NT-proBNP). While serum NT-proBNP is a powerful biomarker in distinguishing the etiology of ascites and monitoring treatment progression, its cost can be prohibitive in low-resource settings. Clinicians practicing under these circumstances may opt to rely on other parameters to manage their patients. We go on further to report a series of 3 patients with cardiac ascites to illustrate how these biomarkers may be employed in the management of this patient population. Clinicians should always keep in mind the differential diagnosis of cardiac failure as a cause of ascites. The resolution of cardiac ascites may serve as a surrogate clinical marker for response to antifailure therapy in lieu of NT-proBNP at resource-scarce centers.     

Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma

ObjectiveTo investigate the effects of hand–foot syndrome (HFS) and fatigue on disease progression and survival in patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma.MethodsA retrospective analysis of patients with advanced hepatocellular carcinoma treated with sorafenib in our hospital from 1 October 2018 to 31 October 2021 was performed, and clinical and pathological data and follow-up results were obtained. Patients were divided into groups according to the severity of HFS and fatigue. Survival analysis among the groups was performed using the Kaplan–Meier method, continuous variables were analyzed using the t-test, and factors associated with survival were evaluated using multivariate Cox regression analysis.ResultsThe study included 150 men and 23 women with a mean age of 60.77 years (range: 40–85 years). The median overall survival (OS), progression-free survival (PFS), and time to tumor progression (TTP) increased with increasing severity of HFS. Conversely, the median OS, PFS, and TTP decreased with increasing severity of fatigueConclusionHFS and fatigue were independent risk factors affecting TTP, PFS, and OS among patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma.